Business Wire

TOM FORD Unveils Black Orchid Reserve Campaign Starring Tilda Swinton

29.8.2025 06:35:00 CEST | Business Wire | Press Release

Share

The quest for exceptional rarity. Introducing Tilda Swinton for the new TOM FORD Black Orchid Reserve campaign.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250828507187/en/

“It is a profound honour for me to play a part in the history of TOM FORD’s legendary Black Orchid. Transformation, the blurring of boundaries and the celebration of magical properties have always drawn me close; Black Orchid Reserve is precisely such an enchantment.” — Tilda Swinton

A celebrated actor and artist, Swinton is a singular presence known for her fearless artistry and transformative performances. An Academy Award, BAFTA and Golden Lion for Lifetime Achievement winner, Swinton defies conventions with elegance, intellect and a visionary approach to cinema. Her work transcends definition, shaping the culture through work in film, art and performance.

TOM FORD creative director Haider Ackermann designed the campaign as a cinematic portrait of rarity in its most heightened form. Lensed by Inez and Vinoodh, the campaign images and video — launching on September 1 — show Swinton in fluid motion. A magnetic force of nature. It is a portrait of a woman who awakens the world around her through gaze and gesture, stillness and strength. She is as rare as the Black Orchid – a flower born of the quest for perfection.

Black Orchid, TOM FORD’s first fragrance, was a revelation when it debuted in 2006. Now, TOM FORD debuts Black Orchid Reserve. The fragrance introduces the Ghost Orchid — a phantom-like flower that is revered as one of the most elusive in the world — with its scent captured by headspace technology the moment the Ghost Orchid blooms. This precious note is a decadent white floral, providing a brilliant contrast to Black Orchid’s rich, dark accords and spice, ushering in a new chapter in the world of TOM FORD’s Black Orchid.

ABOUT TOM FORD

TOM FORD IS A GLOBAL LUXURY HOUSE OFFERING EXCEPTIONAL WOMEN’S AND MEN’S FASHION, ACCESSORIES, EYEWEAR AND BEAUTY.

FOUNDED IN 2005 BY TOM FORD, THE HOUSE IS KNOWN FOR SHARP TAILORING AND SEDUCTIVE ELEGANCE. IT HAS A PRESENCE IN MORE THAN 100 COUNTRIES AND TERRITORIES. THE ESTÉE LAUDER COMPANIES BECAME THE SOLE OWNER OF THE TOM FORD BRAND IN 2023, ESTABLISHING LONG-TERM LICENSES WITH THE ERMENEGILDO ZEGNA GROUP FOR FASHION AND ACCESSORIES, AND MARCOLIN FOR EYEWEAR. HAIDER ACKERMANN WAS APPOINTED CREATIVE DIRECTOR IN 2024.

ABOUT THE ESTÉE LAUDER COMPANIES

The Estée Lauder Companies Inc. is one of the world’s leading manufacturers, marketers, and sellers of quality skin care, makeup, fragrance, and hair care products, and is a steward of luxury and prestige brands globally. The company’s products are sold in approximately 150 countries and territories under brand names including: Estée Lauder, Aramis, Clinique, Lab Series, Origins, M·A·C, La Mer, Bobbi Brown Cosmetics, Aveda, Jo Malone London, Bumble and bumble, Darphin Paris, TOM FORD, Smashbox, AERIN Beauty, Le Labo, Editions de Parfums Frédéric Malle, GLAMGLOW, KILIAN PARIS, Too Faced, Dr.Jart+, the DECIEM family of brands, including The Ordinary and NIOD, and BALMAIN Beauty.

ELC-B

View source version on businesswire.com: https://www.businesswire.com/news/home/20250828507187/en/

Contacts

Media Relations:
Meridith Webster
mwebster@estee.com

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye